CRISPR Is Quietly Becoming a Cure Business
Gene editing moved from headlines to clinics: first approved therapies, then a queue of rare-disease cures.
0 reactions · anonymous
From edit to cure
The first CRISPR therapies target blood diseases with a one-time edit. The pipeline behind them tackles blindness, muscular dystrophy and amyloidosis.
The business model is the twist: one-time cures clash with recurring-revenue pharma economics, forcing new pricing structures.
Building incoffeed — a daily editorial on tech, AI, fintech and business. Co-founder & editor.
Discussion
0// No comments yet — be the first to start the discussion.
